Alzinova AB Revenue and Competitors
Estimated Revenue & Valuation
- Alzinova AB's estimated annual revenue is currently $1.9M per year.
- Alzinova AB's estimated revenue per employee is $155,000
Employee Data
- Alzinova AB has 12 Employees.
- Alzinova AB grew their employee count by 0% last year.
Alzinova AB's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer (CMO) | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
Alzinova AB Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Alzinova AB?
Alzinova AB is a Swedish biopharma company specializing in the treatment of Alzheimer's disease by targeting neurotoxic amyloid-β oligomers. The lead candidate, ALZ-101, is in late preclinical development as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that target the toxic amyloid-β oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201, in early preclinical development, was generated with the AβCC peptide™ technology and the ambition is to expand the pipeline further. The Company's Certified Advisor on Nasdaq First North is Corpura Fondkommission AB, info@corpura.se, +46 (0)768-532 822.
keywords:N/A
N/A
Total Funding
12
Number of Employees
$1.9M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Alzinova AB News
The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - March 2022.
The shareholders of Alzinova AB (publ) reg. no. 556861-8168 (the "Company") are hereby summoned to attend the Annual General Meeting (the...
STOCKHOLM, March 30, 2022 /PRNewswire/ -- Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing disease-modifying...
Other Companies in Mölndal
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.6M | 23 | 5% | N/A |
#2 | $3.7M | 24 | -8% | N/A |
#3 | $4.5M | 24 | 4% | N/A |
#4 | $5.1M | 27 | 8% | N/A |
#5 | $4.5M | 29 | 7% | N/A |